Legacy Wealth Asset Management LLC Sells 450 Shares of Boston Scientific Co. (NYSE:BSX)

Legacy Wealth Asset Management LLC lowered its stake in shares of Boston Scientific Co. (NYSE:BSX) by 1.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,058 shares of the medical equipment provider’s stock after selling 450 shares during the quarter. Legacy Wealth Asset Management LLC’s holdings in Boston Scientific were worth $2,149,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Thoroughbred Financial Services LLC bought a new position in shares of Boston Scientific in the second quarter worth $203,000. J.W. Cole Advisors Inc. increased its holdings in Boston Scientific by 9.2% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 3,989 shares of the medical equipment provider’s stock valued at $307,000 after buying an additional 336 shares during the period. Citizens Financial Group Inc. RI acquired a new position in shares of Boston Scientific in the 2nd quarter valued at approximately $274,000. Edgestream Partners L.P. lifted its holdings in shares of Boston Scientific by 64.7% during the 2nd quarter. Edgestream Partners L.P. now owns 8,796 shares of the medical equipment provider’s stock worth $677,000 after acquiring an additional 3,455 shares during the period. Finally, Axxcess Wealth Management LLC boosted its position in shares of Boston Scientific by 3.7% during the 2nd quarter. Axxcess Wealth Management LLC now owns 10,452 shares of the medical equipment provider’s stock worth $805,000 after acquiring an additional 377 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

BSX has been the topic of several recent analyst reports. Citigroup lifted their price target on Boston Scientific from $98.00 to $107.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Mizuho boosted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. BTIG Research raised their price target on shares of Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Bank of America upped their price objective on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Finally, Royal Bank of Canada raised their target price on shares of Boston Scientific from $95.00 to $98.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Three research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average price target of $97.26.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 14,010 shares of Boston Scientific stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the transaction, the executive vice president now owns 978 shares in the company, valued at $87,306.06. This trade represents a 93.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Edward J. Ludwig sold 4,877 shares of the company’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the sale, the director now owns 39,398 shares of the company’s stock, valued at approximately $3,610,038.74. The trade was a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,989 shares of company stock valued at $2,702,261. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 1.3 %

BSX stock opened at $98.15 on Friday. Boston Scientific Co. has a 1-year low of $59.85 and a 1-year high of $98.31. The stock has a market cap of $144.65 billion, a price-to-earnings ratio of 81.11, a price-to-earnings-growth ratio of 2.48 and a beta of 0.80. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The company’s 50 day moving average is $90.57 and its 200 day moving average is $84.23.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The company had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same period in the previous year, the firm posted $0.50 EPS. The firm’s revenue was up 19.3% compared to the same quarter last year. Sell-side analysts predict that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.